6 November 2026

To
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001

**Scrip Code: 543064**

To
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

**Scrip Symbol: COHANCE**

Dear Sir/Madam,

**Sub: Press Release**

Please find annexed press release on the unaudited financial results of the Company for the quarter and half year ended 30 September 2026.

We request you to take the above on record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
*(formerly,* Suven Pharmaceuticals Limited*)*

Sisira Kumar Mishra
Digitally signed by Sisira Kumar Mishra
Date: 2026.11.06 17:55:30 +05'30'

**Sisir K. Mishra**
*Company Secretary & Compliance Officer*
Encl: as above

# Cohance Lifesciences Announces Q2 & H1FY27 Results

*Q2 delivered sequential growth; H2 to drive YoY growth in revenue and EBITDA*

**Hyderabad/Mumbai, 6 November 2026**

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited), a leading global contract development and manufacturing organisation (CDMO), today announced its unaudited financial results for the second quarter and half year ended 30 September 2026.

## Q2FY27 Financial Performance

- Q2 FY27 revenue from operations was ₹4,767 million, increasing 12.9% sequentially and declining 14.2% year-on-year. Gross margin was 70.8%, compared with 74.6% in Q2 FY26, reflecting an unfavourable business and product mix. Adjusted EBITDA was ₹458 million, with an adjusted EBITDA margin of 10%, compared with 2.2% in Q1 FY27.

## H1FY27 Financial Performance

- H1 FY27 revenue from operations was ₹8,989 million, down 18.6% year-on-year. Gross margin was 71.1%, compared with 73.8% in H1 FY26. Adjusted EBITDA was ₹551 million, with an adjusted EBITDA margin of 6.1%.

**Mr. Umang Vohra, Executive Chairman and Group CEO, said:** *"Q2 reflects an improving business trajectory and the broader Cohance platform beginning to come together. We expect H2 to be materially stronger than H1, with year-on-year growth in both revenue and EBITDA, supported by improving visibility across our businesses. At the same time, we remain focused on progressing our regulatory commitments and maintaining the highest standards of quality and compliance across our facilities. We see significant value potential as we continue to integrate and scale the Cohance platform, and we are still at the beginning of that journey"*

## Key Business Highlights of H1FY27

- Small Molecules: Stronger Q3/Q4 order visibility and multiple commercial reload orders received, supporting improved delivery schedules and H2 recovery
- Secured three significant programmes with large global pharma customers, comprising two commercial and one Phase III programme
- Two molecules moved into commercial supply, with two additional molecules expected over the next 12–15 months, including one with US FDA approval
- NJ Bio successfully delivered two ADC GMP campaigns, including an end-to-end development programme. One customised payload programme is progressing through scale-up
- Nucleic Acid business is seeing strong demand for specialised nucleosides and amidites, with increasing commercial opportunities and larger-scale manufacturing programmes across the Cohance network
- Qualification programmes progressing with two Japanese customers, alongside opportunities with a European innovator and potential manufacturing transfers
- NJ Bio, Inc. was named Runner-Up in the Best Contract Research Organization (CRO) category at the 2026 World ADC Awards, marking seven consecutive years of recognition at the event

## Outlook

H2 FY27 is expected to be materially stronger than H1 FY27, supported by Small Molecule deliveries and reloads, continued resilience in API+, nucleic-acid growth and progressive improvement across the portfolio. Higher revenue conversion, improved utilisation and a better business mix are expected to support progressive margin recovery. The strategic direction remains unchanged.

## About Cohance Lifesciences

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Through its integrated platform and facilities in India and the US, Cohance provides solutions from early development through commercial supply for leading global pharmaceutical companies.

**For more information, please contact: www.cohance.com**


**Cyndrella Carvalho, Head - Investor Relations,**
Cohance Lifesciences Limited
**Tel:** 040 2354 3311
**Email:** cyndrella.carvalho@cohance.com

**Gavin Desa / Konpal Pali**
CDR India
**Tel:** +91 98206 37649 / 76619 08341
**Email:** gavin@cdr-india.com; konpal@cdr-india.com